Blue Cross Blue Shield says insurers protect patients from high drug prices. The real world shows delays, denials, and blame shifting while patients wait, appeal, and deteriorate. A closer look at how insurers deflect responsibility in the drug pricing debate.

The new bipartisan proposal to separate insurers, PBMs, and providers targets the financial structure behind rising costs and denials. This piece explains how ownership concentration reshaped care, why regulation failed, and what structural separation could change for patients.